OKYO Pharma CEO Robert Dempsey Acquires 15,000 Shares at $1.54 Ahead of Phase 3 Trial Launch

CEO Robert J. Dempsey’s Share Purchase Reflects Insider Confidence

Robert J. Dempsey, CEO of OKYO Pharma Limited, executed a direct purchase of 15,000 ordinary shares on the Nasdaq Capital Market at $1.54 per share. This personal investment by the company’s top executive demonstrates strong confidence in OKYO Pharma’s strategic direction and near-term value potential. Insider acquisitions such as this are closely observed by market participants as indicators of management’s belief in the company’s prospects.

The timing of this insider purchase coincides with a pivotal stage in OKYO Pharma’s clinical development as it prepares to initiate its Phase 3 pivotal trial. Management’s decision to invest personal capital underscores their conviction in the viability of the clinical program and the therapeutic promise of the lead candidate. Regulatory disclosure requirements ensure transparency of such insider transactions, which investors often interpret as a positive signal regarding future company performance and shareholder value creation.

OKYO Pharma’s Focus on Neuropathic Corneal Pain and Anterior Segment Eye Diseases

OKYO Pharma Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neuropathic corneal pain (NCP) and anterior segment eye diseases. NCP is a chronic eye pain condition caused by corneal sensory nerve dysfunction, significantly affecting patient quality of life. Causes include diabetes, surgery, chemical injury, or idiopathic origins. The company’s pipeline strategy targets this underserved patient population alongside other anterior segment eye disorders.

By concentrating on neuropathic corneal pain and related anterior segment conditions, OKYO Pharma operates within a specialized ophthalmology niche where existing treatments are limited. This dual focus supports a platform approach to therapeutic development, enabling exploration of multiple indications within related eye pathologies. OKYO Pharma’s ordinary shares trade on the Nasdaq Capital Market, positioning it among small-cap and micro-cap biopharmaceutical firms in growth stages.

Phase 3 Trial to Evaluate Single-Dose Urcosimod for Neuropathic Corneal Pain

OKYO Pharma plans to initiate a global Phase 3 pivotal clinical trial in the second half of 2026, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain treatment. This trial represents a critical milestone as Phase 3 studies are typically the final clinical step before regulatory submission.

The global trial design suggests patient enrollment across multiple regions to expedite recruitment and generate multi-geography safety and efficacy data essential for market authorization. Evaluating urcosimod as a single-dose treatment may enhance patient compliance and simplify healthcare administration compared to multi-dose regimens. The trial’s success will be pivotal for advancing urcosimod toward regulatory review and potential commercialization, with investors closely monitoring clinical efficacy, safety, and differentiation from existing therapies.

Nasdaq Listing and Investor Relations Support

OKYO Pharma’s ordinary shares are listed on the Nasdaq Capital Market, providing liquidity and access to institutional and retail investors interested in early-stage biopharmaceutical companies. The Nasdaq listing enhances visibility within the investment community and facilitates capital raising for ongoing clinical development.

The company maintains a dedicated investor relations function, with Paul Spencer serving as the contact for business development and investor communications via telephone and email. This infrastructure supports transparency and regular engagement with shareholders and market participants.

Details of Insider Transaction and Executive Alignment with Shareholders

CEO Robert J. Dempsey’s acquisition of 15,000 shares at $1.54 each represents a significant personal investment of $23,100, aligning his financial interests with those of shareholders. Such insider purchases often indicate management’s view that the current stock price is attractive and that upcoming milestones, particularly the Phase 3 trial, offer a credible path to value creation.

Regulatory oversight ensures these transactions comply with insider trading laws and disclosure requirements. Public announcements of insider purchases provide transparency and allow investors to gauge management’s commitment to the company’s clinical and commercial strategies. The CEO’s investment ahead of a major clinical milestone may bolster market confidence in OKYO Pharma’s future direction.

Clinical Development Timeline and Regulatory Considerations

The planned Phase 3 trial initiation in H2 2026 sets a defined clinical development timeline. Phase 3 studies typically last 12 to 36 months depending on enrollment and trial complexity. Completion of this trial will inform regulatory submissions to agencies such as the FDA and EMA for potential approval.

The announcement does not specify regulatory pathways, submission timelines, or detailed trial endpoints beyond the enrollment target of approximately 111 patients. Investors will likely focus on trial initiation confirmation, enrollment progress, safety updates, and any interim efficacy results if available. Successful execution of the Phase 3 program is essential for advancing urcosimod toward regulatory review and commercialization.

Competitive Landscape and Unmet Needs in Neuropathic Corneal Pain

Neuropathic corneal pain is a condition with limited effective treatments. Current management includes topical anesthetics, lubricants, and systemic pain therapies, but no definitive disease-modifying drugs exist. The condition causes chronic discomfort, photophobia, and may lead to corneal scarring or vision loss. OKYO Pharma targets this unmet medical need with its novel therapeutic approach.

The ophthalmology biopharmaceutical field is evolving, with growing interest in corneal neuropathy. A successful NCP treatment could position OKYO Pharma competitively and attract partnerships with larger pharmaceutical companies. The single-dose regimen may offer advantages over chronic treatments, potentially improving patient adherence and provider preference. Market participants will evaluate Phase 3 results against competing programs to assess commercial potential.

Financial Outlook and Capital Needs for Phase 3 Execution

Conducting a global Phase 3 trial with approximately 111 patients across multiple sites requires significant funding for clinical operations, recruitment, data management, and regulatory compliance. OKYO Pharma has not disclosed the trial budget, current cash reserves, burn rate, or financial runway. These factors are critical to understanding the company’s ability to fund development without dilutive financing.

Funding sources for clinical-stage biopharmaceuticals typically include venture capital, partnerships, grants, and public equity. OKYO Pharma’s Nasdaq listing facilitates access to public capital markets for potential equity raises. Future fundraising timing and structure will depend on clinical progress, share price, and investor sentiment. Investors should monitor financial disclosures and announcements regarding capital raises or partnerships that may affect ownership and resource allocation.

Investor Watchpoints and Upcoming Catalysts

Key near-term catalysts include formal Phase 3 trial initiation announcements, enrollment milestones, and safety and efficacy updates during the trial. Investors should follow quarterly earnings, investor presentations, and clinical data releases for insights on trial progress and outcomes. Strategic partnerships or licensing deals could also signal external validation of the company’s approach.

Corporate communications such as press releases and SEC filings (10-K, 10-Q, 8-K) will provide ongoing updates on clinical, financial, and strategic developments. Presentations at medical conferences and scientific publications will further inform stakeholders. The ultimate value creation from insider purchases depends on urcosimod’s clinical and regulatory success and the company’s commercialization capabilities. Monitoring trial progression and announcements will be vital for assessing OKYO Pharma’s medium- to long-term prospects.